BioSpace News Archive

Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended March 31, 2021 and provide a corporate business update on Wednesday, May 5, 2021 at 4:30pm EDT/ 2:30pm MT.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021, after the close of the U.S. financial markets

Dr. Cindy Basinski and Team at CMB Research, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure.

Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company”) announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the “Aion Mushroom Preparations” or “Preparations”) showed high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity

Battelle is expanding its long-standing commitment to increasing diversity and fostering inclusion within Science, Technology, Engineering and Math (STEM) careers by investing $200,000 over two years to provide students from Bowie State University and Morgan State University research opportunities as they progress from the classroom to employment.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results for first quarter ended March 31, 2021

Despite continued pandemic The Leukemia & Lymphoma Society remains unstoppable in its quest to end blood cancer

This new, blood-based test successfully identifies individuals with lymph node metastasis associated with high-risk T1 colorectal cancer and potentially could help people with non-high-risk early-stage colorectal cancer avoid unnecessary colon surgery.

After several weeks of negotiation, I am delighted that we have succeeded in agreeing with CVR Global Inc. an amended restructuring agreement.

The tenth annual Pharmaceutical Innovation Index, released today, sees Eli Lilly top the industry for the first time. The Pharmaceutical Invention Index, a ranking of the industry’s best pipelines, sees Bristol-Myers Squibb at No 1.